EU Antibiotic Resistance: What New ECDC Data Reveals for Public Health

EU antibiotic resistance has reached a level that the European Centre for Disease Prevention and Control (ECDC) now links to more than 35,000 deaths every year across the EU and European Economic Area. New ECDC surveillance data confirm that resistance to last-resort antibiotics rose in nine EU member states over the past year, and the bloc remains off track to meet four of its five 2030 antimicrobial resistance targets. For patients, hospitals and health ministries from Lisbon to Warsaw, the message from the latest figures is unambiguous: drug-resistant infections are becoming harder, not easier, to control.

What the New ECDC Data Shows

The ECDC's most recent surveillance findings, drawn from its EARS-Net network of national reference laboratories, show antimicrobial resistance (AMR) climbing across nearly every category of hospital-acquired infection tracked in the EU/EEA. The headline figure, over 35,000 attributable deaths a year, has been a fixture of ECDC reporting for several years, but the newest data show the underlying drivers are still worsening rather than stabilising.

Between 2019 and 2024, the estimated incidence of carbapenem-resistant Klebsiella pneumoniae bloodstream infections rose by 61% across the EU/EEA, according to ECDC's annual epidemiological analysis. Infections caused by third-generation cephalosporin-resistant Escherichia coli, one of the most common causes of bloodstream and urinary tract infections, rose by 5.9% over the same period. The latest surveillance round adds a further warning sign: resistance to carbapenems and other last-resort antibiotics, the drugs clinicians reach for when first-line treatments fail, increased in nine member states within the past year alone.

Taken together, ECDC and the European Medicines Agency (EMA) have jointly concluded that the EU is not on track to meet four of the five AMR reduction targets set by the Council of the EU for 2030, measured against a 2019 baseline. AMR-related healthcare costs across the bloc are now estimated at roughly €11 billion a year, a figure that captures extended hospital stays, second-line treatments and intensive care admissions but understates the human cost to patients and families.

Why Resistance Is Rising Across the EU

Rising antibiotic resistance in the EU stems from a combination of overuse in human medicine, continued use in livestock farming, and gaps in hospital infection control. No single cause explains the trend; it is the accumulation of small failures across healthcare and agriculture that has pushed resistance rates upward.

In healthcare settings, antibiotics are still frequently prescribed for infections that are viral rather than bacterial, or continued for longer than clinically necessary. ECDC's antimicrobial consumption data show only modest and uneven declines in prescribing across member states since 2019, with several countries reporting stagnation or renewed increases. In agriculture, antibiotic use in food-producing animals remains a documented contributor to resistant strains that can transfer to humans through the food chain and the environment, a concern that underpins the EU's "One Health" approach linking human, animal and environmental health policy.

Hospital infection prevention and control also plays a decisive role. Intensive care units, where the sickest patients rely on invasive devices such as catheters and ventilators, remain the primary sites where carbapenem-resistant organisms spread between patients. Suboptimal hand hygiene compliance, delayed isolation of colonised patients and inconsistent screening protocols allow resistant bacteria to move through hospital wards before they are detected.

Which Countries and Infections Are Most Affected

Hospital-acquired resistant infections are concentrated in southern and eastern EU member states, with carbapenem-resistant Klebsiella pneumoniae showing the steepest increases. ECDC surveillance data and peer-reviewed genomic studies consistently place Greece, Italy, Spain and Romania among the countries with the highest burden of carbapenemase-producing organisms.

Romania illustrates the scale of the shift: the prevalence of carbapenem-resistant Klebsiella pneumoniae in national surveillance rose from 4.9% in 2010 to 41.6% in 2024, according to hospital-based studies published this year. Genomic tracing has identified specific high-risk clones, including ST258/512 in Greece, Italy and Spain, and OXA-48-producing strains in Romania, circulating between hospitals through patient transfers.

Southern Europe (Greece, Italy, Spain): highest rates of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Eastern and south-eastern Europe (Romania, and neighbouring non-EU states): fastest recent growth in carbapenemase-producing organisms.
Northern and western member states: generally lower resistance rates, though ECDC notes consumption of broad-spectrum antibiotics has stagnated rather than declined in several countries.

The infections driving the most concern are bloodstream infections and hospital-acquired pneumonia caused by carbapenem-resistant Enterobacteriaceae, because clinicians often have only one or two remaining antibiotic options, and sometimes none at all.

The Social Impact: Who Actually Pays the Price

Behind the surveillance statistics are patients who enter hospital for a routine procedure and leave with an infection that no longer responds to standard treatment. Older adults, people with weakened immune systems, cancer patients undergoing chemotherapy and anyone requiring intensive care are disproportionately affected, since they are most exposed to invasive devices and prolonged hospital stays where resistant organisms spread.

Lower-income households and patients in under-resourced regional hospitals face additional risk. Southern and eastern member states with higher resistance rates often have hospital systems under greater budgetary strain, meaning fewer isolation beds, tighter nursing ratios and slower rollout of rapid diagnostic tests that would otherwise catch resistant infections earlier. A resistant infection that might be treated in days with an effective first-line antibiotic can instead mean weeks of hospitalisation, lost income for working-age patients and their carers, and, in the most severe cases documented by ECDC, death. With AMR now linked to nearly 100 deaths a day across the EU/EEA, the burden falls hardest on exactly the patients least equipped to absorb an extended hospital stay or a costly course of last-resort treatment.

What's Being Done to Tackle It

EU health ministers are under growing pressure to tighten prescribing rules and expand antibiotic stewardship programmes, and several coordinated measures are already underway. The European Joint Action on AMR and Healthcare-Associated Infections (EU-JAMRAI2), backed by roughly €50 million in EU funding, supports all 27 member states, plus Ukraine, Norway and Iceland, in implementing national AMR action plans centred on surveillance, infection prevention and antimicrobial stewardship.

New EU pharmaceutical legislation, agreed in principle by the European Parliament and Council, will introduce compulsory medical prescriptions for all antimicrobials and require pharmaceutical companies to submit antimicrobial stewardship plans as a condition of marketing authorisation. The European Commission has also committed a further €30 million in 2026 to strengthen the global response to antimicrobial resistance, extending EU-funded surveillance and stewardship capacity beyond the bloc's own borders.

ECDC Director Andrea Ammon has repeatedly urged member states not to lose momentum, warning that "we see concerning increases in the number of deaths attributable to infections with antimicrobial-resistant bacteria, especially those that are resistant to last-line antimicrobial treatment." That warning, echoed in the latest joint ECDC-EMA analysis published in The Lancet Regional Health Europe, calls for stronger enforcement of prescribing rules, greater investment in public health laboratory capacity, and more harmonised cross-border action if the EU is to meet its 2030 targets. Readers following broader EU health articles on baba-int.com will recognise this as part of a wider pattern of EU health systems under sustained structural pressure.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

How many people die from antibiotic-resistant infections in the EU each year?

ECDC estimates that antimicrobial-resistant infections cause more than 35,000 deaths annually across the EU/EEA, equivalent to nearly 100 deaths a day, based on its EARS-Net surveillance network data.

Which EU countries have the highest antibiotic resistance rates?

Southern and south-eastern member states, including Greece, Italy, Spain and Romania, report the highest rates of carbapenem-resistant Klebsiella pneumoniae and related hospital-acquired infections, according to ECDC surveillance and genomic tracing studies.

Is the EU on track to meet its 2030 antimicrobial resistance targets?

No. ECDC and EMA's joint analysis concludes the EU is not on track to meet four of the five AMR reduction targets set by the Council of the EU for 2030, measured against a 2019 baseline.

What is the EU doing to reduce antibiotic overuse?

The EU funds the EU-JAMRAI2 Joint Action across all member states, is introducing new pharmaceutical legislation requiring compulsory prescriptions and stewardship plans, and has committed additional funding in 2026 to expand surveillance and stewardship capacity.

Conclusion and What EU Readers Can Do

The latest ECDC data leave little room for reassurance: antibiotic resistance is rising across the EU, last-resort treatment options are narrowing in multiple member states, and the human and financial costs, over 35,000 deaths and roughly €11 billion a year, are already substantial. Patients and healthcare professionals across the bloc can take concrete steps in response.

Only take antibiotics prescribed for a confirmed bacterial infection, and complete the full course exactly as directed rather than stopping early.
Never request antibiotics for colds, flu or other viral illnesses; ask your GP or pharmacist whether an antibiotic is genuinely necessary.
If you are hospitalised, ask about infection prevention measures, including hand hygiene compliance and screening for resistant organisms, particularly before or after surgery.
Healthcare professionals should consult national antimicrobial stewardship guidelines issued under the EU-JAMRAI2 programme and report resistant isolates promptly to national surveillance networks feeding into ECDC's EARS-Net.
Follow national health ministry guidance on antibiotic use in your member state, and check updates from the European Commission's public health directorate for changes to prescribing rules.

For continued coverage of EU public health policy and the financial pressures facing national health systems, visit Baba International, or explore related finance coverage examining the budgetary strain on EU healthcare systems.